Biogenerics: A Step Closer
Executive Summary
Progress on biogenerics inches along, as evidenced by deal between Barr Pharmaceuticals and PLIVA giving Barr rights to market Pliva's version of G-CSF in North America, and by the recent well-attended FDA workshop on follow-on proteins (FOPs). Barr/PlLIVA, the first company/company deal in this field in months indicates that companies still see opportunity despite last year's regulatory setbacks. The FDA workshop, while far from conclusive, hinted at a softening of positions by both opponents and proponents of biogenerics; at least they're talking the same language.
You may also be interested in...
Big Pharma May Be Big Player in Follow-On Biologics Market
This article is a reprint from the April 2008 issue of The RPM Report. As Congress works on an approval pathway for follow-on biologics, generic drug companies are jockeying for investors' attention. But given that most generic manufacturers may be ill-equipped to handle the development of follow-on proteins, some analysts think the real opportunity is where you'd least expect: inside Big Pharma and biotech.
Pliva: Two Steps Forward, One Step Back?
After a fervent US expanstion capped by the surprise $150 million licensing of Indevus OAB treatment Sanctura, proprietary ambitions at the Croatian generics play Pliva may be stalling. Sanctura sales have disappointed, illustrating again the challenges of taking a specialist approach to primary care marketing. Pliva's best bet may be to switch growth engines to its promising biogenerics portfolio.
Novartis/Hexal: Generic Consolidation, and More
Buying Hexal shows Novartis' commitment to generics. The Swiss group also hopes the move will bring more credibility, and better deals, across all of its businesses.